Focusing development on rare autoimmune disorder IgG4-related disease (IgG4-RD) Ongoing Phase 1b/2a clinical trial on track to report topline results by end of 2014 Conference call today at 5:00 p.m. EDT MONROVIA, Calif. , Oct. 28, 2014 /PRNewswire/ -- Xencor, Inc.

- 75% of high IgE subjects had reduction of free IgE below limit of detection following a single intravenous infusion across all dose levels -- Generally well tolerated as an intravenous infusion with transient, asymptomatic thrombocytopenia at doses ≥2.0 mg/kg -

MONROVIA, Calif. , June 10, 2015 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, today reported complete data results from a Phase

Conference call today at 4:30 p.m. EDT

MONROVIA, Calif. , May 4, 2015 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, today reported financial results for the first

MONROVIA, Calif. , May 2, 2016 /PRNewswire/ --  Xencor, Inc. ( NASDAQ : XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer, today reported financial results for the first

-- Phase 1 Data from Subcutaneous Administration Trial of XmAb®5871 Support Biweekly Dosing ---- Management to Host Conference Call Today at 4:30 p.m. ET --

-- Introduced XmAb® IL15 Bispecific Antibody Platform and Presented Preclinical Data on XmAb®24306 at American Association for Cancer Research (AACR) Annual Meeting -- - Completed Public Offering, Raising $245.5M and Extending Cash Runway into 2023 - -- Expect to Initiate Phase 3 Trial of XmAb®5871

-- Management to Host Conference Call at 4:30 p.m. ET today -- MONROVIA, Calif. --(BUSINESS WIRE)--May 9, 2019-- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer, autoimmune diseases, asthma and allergic

-- Management to Host Conference Call at 4:30 p.m. ET Today -- MONROVIA, Calif. --(BUSINESS WIRE)--May 7, 2020-- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases, today reported